Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) andcleaved hmwk
AssigneeTakeda Pharmaceutical Company Limited
InventorsJiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
Life of this patent
Estimating the term…
Abstract
Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
Claims21
-47. (canceled)
A method for identifying a subject having or at risk for hereditary angioedema (HAE), the method comprising:
- (i) providing a biological sample of a subject,
- (ii) contacting the sample with a protease to generate a plurality of digested peptides;
- (iii) measuring the level of a signature peptide in the plurality of digested peptides, wherein the signature peptide is indicative of cleaved high molecular weight kininogen (HMWK);
- and
- (iv) identifying the subject as having HAE or being at risk for HAE attack based on the level of cleaved HMWK, wherein an elevated level of cleaved HMWK in the biological sample as compared with a predetermined reference value indicates that the subject has HAE or is at risk for HAE attack.
A method for identifying a subject having or at risk for hereditary angioedema (HAE), the method comprising:
- (i) providing a biological sample of a subject,
- (ii) contacting the sample with a protease to generate a plurality of digested peptides;
- (iii) measuring the level of a first signature peptide and a second signature peptide in the plurality of digested peptides, wherein the first signature peptide is indicative of cleaved high molecular weight kininogen (HMWK) and the second signature peptide is indicative of intact HMWK;
- (iv) determining the ratio between the first signature peptide and the second signature peptide,
- (v) identifying the subject as having HAE or being at risk for HAE attack based on the ratio between the first signature peptide and the second signature peptide, wherein an elevated ratio of cleaved HMWK to intact HMWK in the biological sample as compared with a predetermined reference value indicates that the subject has HAE or is at risk for HAE attack.
Dependencies are inferred from the claim text.